HighTower Advisors’s Akero Therapeutics AKRO Stock Holding History

HighTower Advisors’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-7,684	Closed	-$365K	–	3656
2025 Q3	$365K	Sell	7,684 -766	-9%	-$37.1K	﹤0.01%	2875
2025 Q2	$451K	Buy	8,450 +1,229	+17%	+$55.8K	﹤0.01%	2608
2025 Q1	$292K	Buy	+7,221	New	+$306K	﹤0.01%	2884

Other funds holding AKRO

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HighTower Advisors's AKRO Position: Q4 2025 in Review

HighTower Advisors sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 7,684 shares — an estimated $365K sold.

HighTower Advisors first reported a position in AKRO in Q1 2025 and held it in 3 quarters. The position peaked at $451K in Q2 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

HighTower Advisors reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
HighTower Advisors sold 7,684 Akero Therapeutics shares in Q4 2025, an estimated $365K.
HighTower Advisors first reported a position in Akero Therapeutics in Q1 2025 and held it in 3 quarters.
HighTower Advisors's Akero Therapeutics position peaked at $451K in Q2 2025.
2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on HighTower Advisors's 13F filing for Q4 2025, filed 6 Feb 2026.